Notice Director’s Report Management Discussion Report on Corporate Auditor’s Report
Balance Sheet Profit and Loss Notes Forming Case Flow Proxy Form

Balance sheet & profit & loss and their schedule

COLINZ LABORATORIES LTD.

BALANCE SHEET AS AT MARCH 31, 2013

  All amounts in Rupees, unless otherwise stated
  Notes  As at   As at 
   March 31, 2013   March 31, 2012 
I EQUITY AND LIABILITIES
 
1 Shareholders' Funds
  (a) Share Capital             35,435,000                35,435,000
  (b) Reserves & Surplus 2             27,350,510
               27,350,510
 
2 Non Current Liabilities
  (a) Long Term Borrowings 3
     22,554,442
               23,917,851
  (b) Deferred Tax Liabilities                3,604,256                  3,100,117
  (c) Other Long Term Liabilities                    147,303                       98,147
  (d) Long Term Provisions                          -                              -  
 
3 Current Liabilities
  (a) Short Term Borrowings
  (b) Trade Payables 4               4,012,688                  9,216,354
  (c) Other Current Liabilities 5               5,651,735                  4,056,768
  (d) Short Term Provisions                          -                              -  
  TOTAL       98,554,294              102,174,747
 
II ASSETS
1   Non-Current Assets 
  (a) Fixed Assets 6
       (i)   Tangible Fixed Assets 39,761,278                42,360,771
       (ii)  Intangible Assets                            -                            -  
       (iii) Capital Work In Progress                            -                            -  
       (iv) Intangible Assets under Development                             -                            -  
  (b) Non-Current Investments 7               3,158,769                  3,158,769
  (c) Deferred Tax Assets (Net)                            -                            -  
  (d) Long Term Loans & Advances 8             13,543,150                13,763,150
  (e) Other Non-Current Assets 9                  599,115                            524,850 
2 Current Assets
  (a) Current Investments                            -                            -  
  (b) Inventories 10 18,605,953 21,333,064
  (c) Trade Receivables  11 12,716,652 10,842,820
  (d) Cash and Cash Equivalents 12 9,383,894 9,258,213
  (e) Short Term Loans and Advances 13 785,483 933,110
  (f) Other Current Assets                          -                              -  
  TOTAL 98,554,294 102,174,747

 

As per our report of even date attached.    
FOR  S. V. BHAT & CO. FOR AND ON BEHALF OF THE BOARD.
FIRM REG.NO.101298W  
Chartered Accountants.    
     
S. V. BHAT Dr.  L. S. Mani N. K. MENON
Proprietor.  Chairman & Managing Director Director
M. No. 37237 .  
   
Place: Mumbai    
Date:15th May, 2013.    

 

(Top)


COLINZ LABORATORIES LTD.

STATEMENT OF PROFIT AND LOSS  FOR THE YEAR ENDED MARCH 31, 2012

All amounts in Rupees, unless otherwise stated
 Year ended   Year ended 
NOTES  March 31, 2012   March 31, 2011 
 I  Revenue from Operations
Sales -Products 14 76,818,336 70,454,561
Other Operating Revenue 323,373                                -
Less : Excise duty                 (5,282,156)                 (4,435,470)
66,019,091 57,023,662
 II  Other Income 15                      368,554                      221,982
 III   Total Revenue (I+II)                 66,387,645                57,245,644
 IV  Expenses
Cost of Materials Consumed 16                 24,417,414                 21,033,670
Purchase of Trading Goods                   3,457,117                   3,045,463
Changes in inventories of finished goods work-in-progress and Stock-in-Trade 17                 (1,095,212)                 (2,310,950)
Employee Benefits Expense 18                  22,543,606                 19,047,690
Finance Cost 19                   1,892,853                   1,560,718
Depreciation and amortization expense 6                   2,599,467                   2,577,525
Other Expenses 20                 11,693,676                 11,506,788
 Total Expenses                 65,508,921                56,460,904
 V  Profit before exceptional and extraordinary items and tax (III-IV)                     878,724                     784,740
 VI  Exceptional items                              -                                  -
 VII  Profit before extraordinary items and tax (V - VI)                     878,724                     784,740
 VIII  Extraordinary Items                              -                                  -
 IX  Profit before tax (VII- VIII)                     878,724                     784,740
 X  Tax expense:
(1) Current tax                     158,337                     133,850
(2) Deferred tax                   (383,863)                     (77,935)
 XI  Profit (Loss) for the period from continuing operations (IX-X)                  1,104,250                     728,825
 XII  Profit/(loss) from discontinuing operations                              -                                  -
 XIII  Tax expense of discontinuing operations                              -                                  -
 XIV  Profit/(loss) from Discontinuing operations (after tax) (XII-XIII)                              -                                  -
 XV  Profit (Loss) for the period (XI + XIV)                  1,104,250                     728,825
 XVI  Earnings per equity share:
(1) Basic                           0.24                           0.16
(2) Diluted                              -  
Significant accounting policies and notes  21
 to the financial statements 

 

As per our report of even date attached.    
FOR  S. V. BHAT & CO. FOR AND ON BEHALF OF THE BOARD.
FIRM REG.NO.101298W  
Chartered Accountants.    
     
S. V. BHAT Dr.  L. S. Mani N. K. MENON
Proprietor.  Chairman & Managing Director Director
M. No. 37237 .  
   
Place: Mumbai    
Date:15th May, 2012.    

 

(Top)


COLINZ LABORATORIES LTD.

NOTES  FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 As at   As at 
 March 31, 2013   March 31, 2012
Notes 1 - Share Capital
a Authorised:
60,00,000 (Previous Year 60,00,000) Equity Shares of Rs.10 each 60,000,000 60,000,000
b Issued, Subscribed and Paid-up:
Issued:
45,76,000 Equity shares of Rs. 10 each.
Subscribed and paid-up:
45,71,000 (Previous Year 45,71,000) Equity Shares of Rs.                         35,435,000                       35,435,000
10 each fully/Partly  paid-up 35,435,000 35,435,000
                                                    
c Par Value per share is Rs. 10  
d Reconciliation of the number of shares outstanding at the beginning and at the end of the reporting period;
Particulars No.  Rs.  No.  Rs. 
Shares outstanding at the beginning of the year  3543500 35,435,000 3543500 35,435,000
Shares Issued during the year  0 0 0 0
Shares bought back during the year 0 0 0 0
Any other movement (please specify) 0 0 0 0
Shares outstanding at the end of the year     3543500    35,435,000 3543500 35,435,000
e shares in the company held by each shareholder holding more than 5 percent shares specifying the number of shares held
Name of the shareholder No. of shares  % of holding No. of shares  % of holding
L S Mani 705050 15.4244 705050 15.4244
Vijaya Mani 386000 8.4445 208750 8,4445
f For the period of five years immediately preceding the date as at which the Balance Sheet is prepared: Aggregate No. of Shares (for last 5 Financial Years)
Particulars  
   
Fully paid up pursuant to contract(s) without payment being received in cash Nil
Fully paid up by way of bonus shares Nil
Shares bought back Nil
g Unpaid Calls No. of shares Rs. No. of shares Rs.
By Directors 0 0 0 0
By Officers 0 0 0 0
By Others 2055000 10,275,000 2055000 10,275,000
Notes 2 - Reserves & Surplus
a. Capital Reserves:
State Special Capital Incentive Received Rs. Rs. Rs. Rs.
         Opening Balance 3,500,000   3,100,000  
        (+) Current Year Transfer 0   400,000  
        (-)  Written back in the current year 0   0  
        Closing balance   3,500,000   3,500,000
b. Share Premium Account
         Opening Balance 15,220,250   15,220,250  
        (+) Current Year Transfer 0   0  
        (-)  Written back in the current year 0   0  
        Closing balance   15,220,250   15220250
c. Profit & Loss Account
         Opening Balance 7,630,260   6,526,010  
        (+) Current Year Transfer 798,360   1,104,250  
        (-)  Transfer to Other Reserves 0   0  
        Closing balance   8,428,620   7,630,260
Total [a+b+c]   27,148,870   26,350,510
         
         

 

COLINZ LABORATORIES LTD.

NOTES  FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 As at   Total As at 
 March 31, 2013   March 31, 2012 
Notes 3 - Long Term Borrowings
Secured-From Banks
Cash Credit Account with Bank of Baroda 8,360,307 8,794,822
[Secured by Hypothecation of Stock in Trade/Book debts]
Term loan from Bank of Baroda    -    1,394,146
[Secured by hypothecation of plant and machinery at Sinnar 
 factory]
Car Loan from Axis Bank 590,064 712,898
[Secured against hypothecation of car]
8,950,371 9,507,720
Unsecured Loans -Others
Sales tax deferred (Interest free) 13,604,071 14,410,131
[As per Package Scheme of Incentive of Maharashtra state 
 government and includes VAT and CST]
13,604,071 14,410,131
   
Total 22,554,442 23,917,851
Notes 4- Trade Payables
Sundry Creditors: 
a) Micro and small enterprises *                         -                           -  
b) Others 4,012,688 9,216,354
* [Determined to the extent such particulars have been identified
on the basis of information available with the Company. This has
been relied upon by the auditors]
4,0012,688 9,216,354
Notes 5- Other Current Liabilities
Statutory liabilities  1,377,700 875,131
Other Liabilities 3,605,098 2,651,184
Provisions 668,937 530,453
5,651,735 4,056,768
   

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE BALANCE SHEET AS AT MARCH 31, 2013

Notes 6 - Fixed Assets

DESCRIPTION GROSS BLOCK DEPRECIATION NET BLOCK
  As at 1.4.2012 Additon in Deduction As at 31.3.2013 As at 1.04.2012 Depreciation  Deduction Up to 31.3.2013 As at 31.3.2013 As at 31.3.2012
    2012-13       for the year        
             
A. Tangible Assets            
LAND 2574350 0 0 2574350 0 0 0 0 2574350 2574350
[Including Land Developing Exps]            
BUILDING- Factory 24027330 0 0 24027330 7498823 802513 0 8301336 15725994 16528507
BUILDING-Office 6580717 0 0 6580717 921164 107266 0 1028430 5552287 5659553
PLANT & MACHINERY 11187512 0 0 11187512 5720981 531407 0 6252388 4935124 5466531
LABORATORY EQUIPMENTS 1570542 0 0 1570542 769991 74601 0 844592 725950 8800551
FACTORY EQUIPMENTS & TOOLS 3223653 0 0 3223653 1442811 153124 0 1595935 1627718 1780842
ELECTRICAL INSTALLATION 2377531 0 0 2377531 1264974 112933 0 1377907 999624 1112557
CENTRAL A.C. PLANT 8176691 0 0 8176691 8176691 2586468 0 388393 2974861 5201830
OFFIICE EQUIPMENTS 592660 0 0 592660 408866 28151 0 437017 155643 183794
COMPUTER 644888 0 0 644888 592996 17432 0 2493422 976018 1195633
FURNITURE & FIXTURE 3469439 0 0 3469439 2273807 219615 0 2493422 976018 1195633
VEHICLES 1935457 0 0 1935457 519119 183868 0 702987 1232470 1416338
Total Tangible Assets 66360770 19810 0 66380580 24000000 2619303 0 26619303 39761278 42360771
                     
B. Intangible Assets 0 0 0 0 0 0 0 0 0 0
                     
TOTAL ASSETS 66360770 19810 0 66380580 24000000 2619303 0 26619303 39761278 42360771
PREVIOUS YEAR 65969729 996363 605322 66360770 21838838 2599467 438305 24000000 42360771 44130891

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 As at   Total As at 
Face Value No. of shares  March 31, 2013   March 31, 2012
Notes 7- Non-Current Investments
(a)   Equity shares [fully paid, quoted]
3i Infotech 10 600 30000 30000
Ansal Properties & Infrastructure Ltd. 5 200 101,926 101,926
Arvind Ltd 10 500 60681 60681
Bajaj Holdings & Investments Ltd. 10 50 28678 28678
Bajaj Auto  Ltd. 10 100 73319 73319
Bajaj Finserv Ltd. 5 50 27770 27770
Bank of Baroda 10 500 118534 118534
Bank of Maharashtra 10 300 6900 6900
Bharat Forge Ltd. 2 30 3804 3804
Bharti Shipyard Ltd. 10 200 64841 64841
Cairn India Ltd 10 1015 162400 162400
CESC Ltd  10 200 128627 128627
Coal India Ltd 10 88 21560 21560
Eveready Industries Ltd. 5 500 17645 17645
GTL Infrastructure Ltd 10 213 4000 4000
Gujarat Sidhee Cement Ltd 10 1000 24186 24186
HFCL Ltd. 1 500 12192 12192
HDFC  Ltd. 2 100 64762 64762
HDIL 10 100 14505 14505
Hindustan Organic Chemicals Ltd 10 1000 66283 66283
Hindustan Oil Exploration Co Ltd 10 500 81322 81322
IDBI Ltd 10 200 15717 15717
IDFC Ltd 10 2000 164446 164446
Idea Cellular Ltd 10 990 130834 130834
IRB Infrastructure  ltd 10 100 16457 16457
Jagran Prakashan Ltd 2 143 27967 27967
Kausalya Infrastructure Ltd 10 176 10560 10560
Kingfisher Airlines 10 200 10641 10641
Lanco Infrastructure Ltd 1 3210 77040 77040
Macleod Russels Ltd 5 250 8823 8823
Mahindra Lifespace Developers 10 200 184668 184668
Maars Software Ltd 10 5000 57340 57340
Morepen Laboratories Ltd. 2 500 7455 7455
NTPC Ltd 10 500 71801 71801
Neyveli Lignite Ltd. 10 400 22868 22868
Panama Petrochem Ltd 10 250 32369 32369
Polaris Software Lab Ltd. 5 200 32299 32299
Punj Lloyd Ltd 2 500 99416 99416
Pyramid Saimira Theatre Ltd 10 60 6000 6000
Ranbaxy Labs. Ltd. 5 100 46004 46004
Reliance Capital Ltd 10 10 1130 1130
Reliance Communication Ltd 5 200 33654 33654
Reliance  Infrastructure 10 15 6348 6348
Reliance Power Ltd 10 74 7358 7358
Simplex Infrastructure Ltd 2 200 76982 76982
SeaMac 10 1000 192315 192315
Sesa Goa 1 100 28407 28407
Sonata Software Ltd 1 1000 52218 52218
Spicejet Ltd 10 250 15138 15138
Tamilnadu Petroproducts Ltd. 10 500 17290 17290
Tanla Solutions Ltd 1 50 6625 6625
Tata Tele (Mah) Services Ltd. 10 700 20634 20634
Unitech Ltd 2 200 44887 44887
United phosphorus 2 100 14083 14083
Voltamp Transformers Ltd 10 100 63163 63163
Wipro Ltd 2 83 13537 13537
Total (a)           2,758,769            2,758,769
[The market value of the quoted shares is Rs. 2,441,536.00 ]
(a)   Mutual Funds & Others (Un-Quoted)
UTI Master Value Fund 33.89 8852.169             300,000                 300,000
JM Infra & Agricultural Fund 10 10000                 100,000                 100,000
Total (b)               400,000                400,000
     
Total Investments [a+b]  3,158,769            3,158,769
     

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 As at   Total As at 
 March 31, 2013   March 31, 2012 
Notes 8 - Long Term Loans & Advances
Security Deposits               713,150 713,150
Loans to Companies 12,830,000 13,050,000
13,543,150 13,763,150
Notes 9- Other Non-Current Assets
Cash and Cash Equivalants
Fixed Deposits maturing after 12 months 599,115 524,850
              599,115 524,850
Notes 10 - Inventories 
Raw Materials [Valued at the lower of cost (first in first out) and estimated net realisable value] 1,521,807 2,468,041
Packing Materials [Valued at the lower of cost (first in first out) and estimated net realisable value] 1,260,417 1,339,510
Work-in-Progress [Valued at the lower of cost and estimated net realisable value] 639,990 59,875
Finished Goods [Valued at the lower of cost and estimated net realisable value] 15,183,739 17,465,638
18,605,953 21,333,064
Notes 11 - Trade Receivables
(Unsecured and considered good)
Debts Outstanding For a Period Exceeding Six Months 1,322,144 1,243,083
Other Debts 11,394,508 9,599,737
     
12,716,652 10,842,820
Trade Receivable stated above include debts due by:
Directors *                         -                           -  
Other officers of the Company *                         -                           -  
Firm in which director is a partner *                         -                           -  
Private Company in which director is a member                         -                           -  
*Either severally or jointly 
Notes 12 - Cash and Cash Equivalents
Cash in Hand 289,622 358,547
Balances with Banks on:
 -  Current Accounts 2,885,346 5,135,607
 -  Fixed Deposit Accounts  6,208,926 3,764,059
 Less: Restricted Cash                         -                            -  
9,383,894 9,258,213
Notes 13 - Short Term Loans and Advances
(Unsecured and considered good, unless otherwise stated)
a Loans and advances to related parties                          -                           -  
b Others
Balances With Central Excise Authorities 69,480 53,999
132,617 Advance to Employees 132,617 236,778
8 Advance to Suppliers/Service Providers - -
Pre-paid Expenses 131,654 141,001
1   304,075 304,075
Tax Deducted at Source and Advance Tax 147,657 197,257
  785,483 933,110

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 Year ended   Year ended 
 March 31, 2013   March 31, 2012 
Notes 14 - Operating Revenue
Sale of Products 76,8,818,336 70,454,561
Other Operating Revenue 323,373 -
77,141,709 70,454,561
Notes 15 - Other Income
Interest on:
( - Bank Deposits [including tax deducted at source Rs.31,867 ) 576,814 320,777
   (Previous year Rs. 15,281)]
 - Dividend 39,653 47,777
Insurance Claim Recevied 158,132 -
Profit on Sale of shares                          -                     65,679
774,599 368,554
Notes 16- Cost of Materials Consumed
Opening Stock 3,807,551 2,597,421
Add: Purchases  20,376,219 25,627,544
24,183,770 28,224,965
Less: Closing Stock             (2,782,224)             (3,807,551)
21,401,546 24,417,414
Notes 17 -Changes in inventories of finished goods work-in-progress and Stock-in-Trade
Opening Stock:
 - Finished Goods 17,465,638 16,262,247
 - Work-in-Progress 59,875 168,054
17,525,513 16,430,301
Less: Closing Stock:
 - Finished Goods 15,183,739 17,465,638
 - Work-in-Progress 639,990 59,875
15,823,729 17,525,513
1,701,784 1,095,212
Notes 18 - Employee Benefit Expense
Salaries and Allowances 24,899,477 21,762,946
Contribution to Provident and Other Funds 650,618 593,242
Gratuity  198,450 187,400
25,748,545 22,543,606
   

 

(Top)


COLINZ LABORATORIES LTD.

NOTES FORMING PART OF THE FINANCIAL STATEMENTS

All amounts in Rupees, unless otherwise stated
 Year ended   Year ended 
 March 31, 2013   March 31, 2012 
Notes 19 - Finance Cost
Interest Expences: 2,020,580 1,892,853
                             
2,020,580 1,892,853
Notes 20 - Other Expense
Block & Designs 14,175 30,675
Consumables 237,065 173,618
Laboratory Expenses 96,847 92,405
AC Rental Charges 158,555 175,848
Office Rent               180,000               180,000
Analytical Charges 275,893 288,708
Office Expenses 624,279 572,832
Conveyance 434,610 373,022
Motor Car Expenses 194,208 171,898
Factory Security Expenses 320,356 274,759
Repairs and Maintenance:
- Plant and Machinery 169,244 36,022
- Building 108,817 269,474
- Others 192,884 195,600
Freight & Forwarding 1,511,573 1,390,682
Insurance 97,757 116,670
Loan License Charges Paid 1,097,720 1,312,568
Auditors’ Remuneration  80,652 90,446
Power & Fuel 863,163 710,954
Printing & Stationery 175,328 105,900
Books & Periodicals 10,200 30,000
Postage & Telegram 323,886 345,243
Legal & Professional Fees 576,461 413,975
Loss on sale of assets - 120,017
Taxes & License Fees 216,802 318,568
Society Maint. Charges 71,027 71,402
Telephone Charges 407,396 439,975
Travelling Expenses 826,662 614,895
Commission on sales 919,548 927,386
Directors' Remuneration 1,721,000 1,711,000
Advertisement (Recruitment & Statutory) 156,549 119,903
Water Charges 20,032 19,964
12,082,689 11,693,676
   

 

(Top)


 

SCHEDULE 21: SIGNIFICANT ACCOUNTING POLICIES AND NOTES TO THE FINALCIAL STATEMENTS :-

a) Significant Accounting Policies:

i]   General :
The Financial statements are prepared under historical cost convention on an accrual basis and comply with the accounting standards referred to in Section 211 ( 3C ) of the Companies Act, 1956.

ii]  Fixed Assets:
Fixed assets are stated at original cost net of tax / duty credits availed, if any.

iii] Capital work in progress:
The capital work in progress as on 31-03-2012 is Rs. Nil

iv]  Depreciation :
Fixed Assets are depreciated under Straight Line Method. The applicable rates are as provided under Schedule XIV to the Companies Act, 1956. Depreciation on additions / deletions of  assets during the year is provided on a pro-rata basis.

v]  Inventories:
Raw materials and packing materials are valued at cost on FIFO basis as per revised Accounting Standard AS-2 of the Institute of Chartered Accountants of India. Finished goods and semi-finished goods are valued at lower of cost or net realizable value.

vi] Investments:
Investments are stated at cost.

vii] Sales:
Sales are recognized at the time of dispatch of goods. All sales are shown inclusive of excise duty and exclusive of Sales Tax (VAT).

viii] Other income:
Includes  interest on Fixed Deposits with Bank, dividends received and capital gains on the shares sold.

ix]  Research and Development Expenses:
No capitalization of Research and Development expenses is made since no capital expenditure on research and development expenditure has been incurred during the year.

x]  Foreign Currency Transactions:
Export earnings of Rs.Nil (Previous Year - Rs.NIL)
Foreign Exchange Outgo of Rs.NIL (Previous Year – Rs. NIL /-)

xi] Retirement Benefits:
Retirement benefit in respect of gratuity is not provided for, and liability is not         
ascertained.
Privilege leave entitlement: Privilege leave entitlements are recognized as a liability as and when the same is encashed by the employees.
Provident Fund: Contribution to Government provident Fund are made as per the provisions regularly.

b) The figures of previous year have been regrouped wherever necessary.

c) As per the available records, there is no outstanding dues to enterprises registered under Micro, Small and Medium Enterprises Development Act, 2006, at the end of the year. Further, no interest has been paid or payable on delayed payment of dues, if any, to such enterprises during the year

d) Estimated amount of contracts remaining to be executed on capital account and not provided for: Rs.Nil     [ Previous Year : Rs. Nil  ]

e) Contingent Liabilities:
Bills Discounted and Purchased  -  Rs. Nil (Previous Year Rs. Nil )
Others                                         -  Rs. Nil (Previous Year Rs. Nil )

f) Auditors Remuneration :                                                             

  2011-2012  2010-2011
Audit Fees

Rs.   66,180

Rs.   55,150

Tax Audit Fees

Rs.   11,030

Rs.   11,030

Other services

Rs.   13,236

Rs.   18,916

Total

Rs.   90,446

Rs.   85,096

 

g) Segment Reporting

The Company is engaged in pharmaceutical formulation business which as per Accounting Standard – AS 17 is considered the only reportable business segment.

h) Related party transaction

As required by Accounting Standard – AS 18 ‘Related Parties Disclosure’ issued by the Institute of Chartered Accountants of India are as follows :

   (a) Key Management personnel              (b)  Details of Transactions.
(i)  Dr. L. S. Mani.                                          Remuneration paid Rs.8,40,500/-
Rent paid for the premise hired Rs. 1,80,000/-

i) Earning per share

As per Accounting Standard – AS 20 on ‘Earning per Share’ issued by the Institute of Chartered Accountants of India, the earning per share of the Company is Rs. 0.24.

j) Accounting for Taxes on Income.

In accordance with the AS-22, Accounting for Taxes on Income, issued by the Institute of Chartered Accountants of India, deferred tax resulting from timing differences between book and tax profits is accounted for, at the current rate of tax, to the extent the timing differences are expected to crystallize. The deferred tax asset arising on account of brought forward unabsorbed depreciation is recognized only to the extent there is a reasonable certainty of realization.

k) AS – 28 Impairment of Assets.
As on the Balance Sheet date the carrying amounts of the assets net of accumulated depreciation is not less than the recoverable amount of those assets. Hence there is no impairment loss on the assets of the company.

In the opinion of Board of Directors, the Current Assets, Loans and advances have a value which on the realization in the ordinary course of business would at least be equal amount stated in the Balance sheet.

l) With regard to loan given to Company, the Board of Directors are of the opinion that no  interest should be provided in the accounts as the principle amount has not been recovered, Further, no provision for doubtful debt is required to be made as the amount is expected to be recovered in due course.

m) Deferred Tax :
The break up of the deferred tax liability as at 31st March, 2012 is as under:

 

2011-12
Rupees

2010-11
Rupees

Deferred Tax Liability :

 

 

Difference between book depreciation and
depreciation as per Income Tax Act, 1961.

63,62,909

64,30,675

 

63,62,909

64,30,675

Deferred Tax Assets:

32,62,792

29,46,695

Net Deferred Tax  Liability

31,00,117

34,83,980

     

n) The Share Capital includes 4,00,000 Equity Shares of Rs. 10/- each, allotted as fully paid   Bonus Shares  by capitalisation of Capital Reserves in 1994-95.

o) Additional information pursuant to the provisions of paragraph 3, 4C and 4D of Part II of   Schedule VI  to the Companies Act, 1956, as certified by the Directors.Quantitative and Turnover information  for the year ending 31st March, 2012.(Previous year figures are regrouped wherever necessary

i] Manufacturing  Activities :                                                                                                 [Rupees in Lacs]

     
Opening Stock
Closing Stock
Turnover

Class

Units

Actual
production

Qty.

Value

Qty.

Value

Qty.

Value

Tablets

Nos.

121.859

37.990

50.27

41.890

54.09

117.959

188.74

 

in Lacs

137.800)

(26.500)

(52.41)

  (37.990)

(50.27)

(126.31)

(179.10)

 

Capsules

Nos.

83.684

22.790

60.56

15.594

54.08

90.88

324.44

 

in Lacs

(99.870)

(12.030)

(35.74)

(22.790)

(60.56)

(89.11)

(252.59)

 

Liquids

Ltrs.

21090.180

 5605.770

16.88

7697.560

27.34

18998.39

68.53

 

 

(19051.160)

(5384.400)

  (12.12)

(5605.770)

(16.88)

(18829.79)

(58.53)

 

Ointments

Kgs 

3051.73

1256.330

17.88

1385.855

21.58

2922.205

      45.59

 

 

(3739.535)

(816.025)

  (14.68)

(1256.330)

  (17.88)

  (3299.23)

      (49.59)

 

Notes :

  • Installed capacity is based on one shift working as certified by the management and  accepted by the  Auditors without verification being a technical matter.

  • Actual production includes production under Loan License arrangements.

  • Figures in brackets are of previous year.

ii] Particulars of Goods Traded:                                                                                              [Rupees in Lacs]

Class Units Opening Stock Purchases Sales Closing Stock

 

 

Qty.

Value

Qty.

Value

Qty.

Value

Qty.

Value

Liquids

 Ltrs.

483.200

1.24

7253.000

13.28

5591.400

18.69

2144.800

6.67

 

in Lacs

(979.200)

(2.53)

(4124.200)

 (7.67)

(4620.200)

(14.32)

(483.200)

(1.24)

 

Injectables

Nos.

70.646

7.45

-

-

70.646

8.84

-

-

 

in Lacs

(13.860)

(2.87)

(134.606)

(6.74)

(77.820)

(10.98)

(70.646)

(7.45)

 

Capsules

Nos.

1.750

 5.69

9.167

17.49

9.732

37.69

1.185

3.84

 

in Lacs

(0.530)

(1.73)

 (8.580)

(16.04)

(7.360)

(30.60)

(1.750)

(5.69)

 

Tablets

Nos.

1.000

2.65

4.804

3.80

3.434

12.02

     2.370

7.05

 

in Lacs

(3.880)

(11.61)

 -

-

  (2.880)

(7.65)

    (1.000)

(2.65)

 

iii] The quantity and value of consumption of raw materials

Raw Materials (Bulk Drugs) Quantity (Kgs.) Value (Rupees in Lacs)
    2011-12 2010-11 2011-12 2010-11

1

Calcium Pantothenate

456

462

3.39

3.04

2

Vitamin E

330

368

5.90

8.81

3

Meclizine

250

180

20.34

13.58

4

Paracetamol

2150

2450

4.98

6.61

5

Chlorazoxazone

425

300

3.68

1.64

6

Isox suprine Hcl

17

17

2.67

2.15

7

Riboflavin  ( B2)

92

75

2.39

3.74

8

Niacinamide

382

430

2.44

3.45

9

Thiaminemono (B1)

74

80

1.18

1.67

10

Spirulina

4156

2829

22.29

13.77

11

Clindamycin Phosphate

25

5

2.43

1.09

12

Progesterone

150

125

23.92

18.10

13

Menthol

175

170

2.75

1.97

14

Propylene Glycol

1635

1590

2.13

2.54

15

Sorbitol

2227

600

1.16

0.24

16

Fish Oil

360

160

3.63

1.42

17

Folic Acid

90

-

2.82

-

18

Sugar

12550

7500

3.85

2.17

19

P V P K

150

-

1.22

-

20

Ofloxacin usp

120

95

3.20

1.88

21

Quinine Sulphate

25

30

1.71

2.03

22

Mat SR Base III

84

106

1.49

1.76

23

Ornidazole

300

237

3.26

2.26

24

Empty Gelatin Capsule

 

 

10.75

10.39

25

Others

 

 

23.09

18.62

 

                                    Total :

 

 

156.67

 122.93

 

As per our report of even date attached.    
FOR  S. V. BHAT & CO. FOR AND ON BEHALF OF THE BOARD.
FIRM REG.NO.101298W  
Chartered Accountants.    
     
S. V. BHAT Dr.  L. S. Mani N. K. MENON
Proprietor.  Chairman & Managing Director Director
M. No. 37237 .  
   
Place: Mumbai    
Date:15th May, 2012.    

 

(Top)

Contact:
A/101, Pratik Estate,
Mulund Link Road,
Next to Fortis Hospital,
Mumbai-400078.
Tel.: 91-22-25668002/3
Fax: 91-22-25668006.
Email: cllfindoc@yahoo.com
Website:www.findoc-cll.in
Email:info@findoc-cll.in